Integrate the Patient Perspective from the Clinic, Benefit-Risk Analyses, & Delivery to Minimize Side Effects & Maximize Commercial Potential of Your JAK Inhibitor

Welcome to the 3rd JAK Inhibitors Drug Development Summit: The First & Only Meeting Dedicated to JAK Inhibitor Development in Dermatology & Beyond

Following the success of two virtual experiences, the 3rd JAK Inhibitors Drug Development Summit is making its way to Boston, MA as the only meeting specializing in global end-to-end JAK Inhibitor drug development for chronic disease 

We are world’s primary summit uniting this niche community of world-leading experts from a range of therapeutic backgrounds all tied together by one thing, treating chronic dermatologic, autoimmune, oncologic and many more inflammatory indications through JAK inhibition.  

This remains the only end-to-end industry meeting committed to delivering new JAK inhibitor therapeutics to a global market through collaboration. 2022’s summit bestows an unrivaled prospect to industry experts;

  • Hosting conversations around JAKi safety and balancing the benefit and risk with the need to consider and change patient perspective always at the forefront
  • Reviewing opportunities to efficiently foray into chronic indications of unmet need to diversify your pipeline
  • Embracing discussion around topical, oral and alternative drug delivery methods to maximize efficacy and minimize off target effects
  • Exploring JAK selectivity as we begin to harness the potential of precision medicine

Among Our Expert Speakers For 2022

Brett King MD

Associate Professor, Dermatology

Yale University School of Medicine

Kendall Marcus

Director Dermatology & Dentistry


Patrick Burnett

Senior Vice President & Chief Medical Officer

Arcutis Therapeutics

Robert Clarke

Chief Executive Officer & Co-Founder

Kinaset Therapeutics

William Damsky MD


Yale New Haven Hospital

Attending Companies Include

Companies Attending

Hear What Past Attendees Have To Say

The content was fantastic. The speakers were wonderful as well. It was a great educational forum and it is nice to see experts in academia, government, and industry working towards one goal of bringing safe and innovative products for patients.” 

Jennifer Lee, Senior Medical Science Liaison, Sanofi Genzyme 

"This forum is an opportunity to interface with industry to identify and begin to address the challenges and opportunities in the vast potential of JAK inhibitors across medicine." 


Brett King, Associate Professor of Dermatology, Yale School of Medicine